Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

  • More than half of patients with BRAF-mutated advanced melanoma taking Tafinlar + Mekinist were alive and free of a relapse at 5-years1
     
  • Study conclusions are drawn from the largest dataset and longest follow-up to date of patients with BRAF-mutated melanoma treated with targeted therapy following the surgical removal of their cancer1,2
     
  • Data are from the five-year follow-up of the COMBI-AD trial presented at the ASCO20 Virtual Scientific Program1

Basel, May 29, 2020 …

/by

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation

  • Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe
     
  • Phase III trial showed Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in this patient population, compared to fulvestrant alone
     
  • PIK3CA mutations affect approximately 40% of HR+/HER2- advanced breast cancer patients and are linked to cancer growth and a poorer disease prognosis in the metastatic setting

…

/by